These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 28796997)

  • 1. Dynamics of Inflammatory Factors in Aqueous Humor during Ranibizumab or Aflibercept Treatment for Age-Related Macular Degeneration.
    Motohashi R; Noma H; Yasuda K; Kotake O; Goto H; Shimura M
    Ophthalmic Res; 2017; 58(4):209-216. PubMed ID: 28796997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraocular Vascular Endothelial Growth Factor Levels in Pachychoroid Neovasculopathy and Neovascular Age-Related Macular Degeneration.
    Hata M; Yamashiro K; Ooto S; Oishi A; Tamura H; Miyata M; Ueda-Arakawa N; Takahashi A; Tsujikawa A; Yoshimura N
    Invest Ophthalmol Vis Sci; 2017 Jan; 58(1):292-298. PubMed ID: 28114590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
    Jørstad ØK; Faber RT; Moe MC
    Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
    Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
    Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes.
    Gharbiya M; Giustolisi R; Marchiori J; Bruscolini A; Mallone F; Fameli V; Nebbioso M; Abdolrahimzadeh S
    Curr Eye Res; 2018 Mar; 43(3):391-396. PubMed ID: 29166140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration.
    Abdin AD; Suffo S; Asi F; Langenbucher A; Seitz B
    Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1671-1677. PubMed ID: 31144055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Intraocular Cytokine Profile and Therapeutic Response in Persistent Neovascular Age-Related Macular Degeneration.
    Rezar-Dreindl S; Sacu S; Eibenberger K; Pollreisz A; Bühl W; Georgopoulos M; Krall C; Weigert G; Schmidt-Erfurth U
    Invest Ophthalmol Vis Sci; 2016 Aug; 57(10):4144-50. PubMed ID: 27537264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PHARMACOKINETIC STUDY OF INTRAVITREAL AFLIBERCEPT IN HUMANS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Do DV; Rhoades W; Nguyen QD
    Retina; 2020 Apr; 40(4):643-647. PubMed ID: 31145389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
    Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
    BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indocyanine green angiography findings in patients with neovascular age-related macular degeneration refractory to ranibizumab switched to aflibercept.
    Calvo-Gonzalez C; Reche-Frutos J; Fernández-Vigo JI; Donate-López J; Serrano-García I; Fernández-Pérez C
    Int Ophthalmol; 2019 Nov; 39(11):2441-2448. PubMed ID: 30767090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration.
    Kanadani TCM; Dos Reis Veloso CE; Dorairaj S; Nehemy MB
    Ophthalmic Res; 2017; 58(1):18-26. PubMed ID: 28301850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is There Any Difference between Ranibizumab and Aflibercept Injections in Terms of Inflammation Measured with Anterior Chamber Flare Levels in Age-Related Macular Degeneration Patients: A Comparative Study.
    Demirel S; Bilici S; Batıoğlu F; Özmert E
    Ophthalmic Res; 2016; 56(1):35-40. PubMed ID: 27027523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
    Steinle NC; Du W; Gibson A; Saroj N
    Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for age-related macular degeneration.
    Sawada T; Wang X; Sawada O; Saishin Y; Ohji M
    Clin Exp Ophthalmol; 2018 Jan; 46(1):46-53. PubMed ID: 28621038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aqueous humor cytokine levels in patients with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration.
    Sakurada Y; Nakamura Y; Yoneyama S; Mabuchi F; Gotoh T; Tateno Y; Sugiyama A; Kubota T; Iijima H
    Ophthalmic Res; 2015; 53(1):2-7. PubMed ID: 25472810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration.
    Yun C; Oh J; Ahn J; Hwang SY; Lee B; Kim SW; Huh K
    Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1693-702. PubMed ID: 26781585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study.
    Augsburger M; Sarra GM; Imesch P
    Graefes Arch Clin Exp Ophthalmol; 2019 Sep; 257(9):1889-1895. PubMed ID: 31256237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration.
    Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y
    Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.